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Abstract
Background: Autism spectrum disorders are neurodevelopmental conditions with severe impairments in social
communication and interaction. Pioneering research suggests that oxytocin can improve motivation, cognition
and attention to social cues in patients with autism spectrum disorder. The aim of this clinical trial is to characterize
basic mechanisms of action of acute oxytocin treatment on neural levels and to relate these to changes in different
levels of socio-affective and -cognitive functioning.
Methods: This clinical study is a randomized, double-blind, cross-over, placebo-controlled, multicenter functional
magnetic resonance imaging study with two arms. A sample of 102 male autism spectrum disorder patients,
diagnosed with Infantile Autistic Disorder (F84.0 according to ICD-10), Asperger Syndrome (F84.5 according to
ICD-10), or Atypical Autism (F84.1 according to ICD-10) will be recruited and will receive oxytocin and placebo
nasal spray on two different days. Autism spectrum disorder patients will be randomized to determine who
receives oxytocin on the first and who on the second visit. Healthy control participants will be recruited
and case-control matched to the autism spectrum disorder patients. The primary outcome will be neural
network activity, measured with functional magnetic resonance imaging while participants perform socio-
affective and -cognitive tasks. Behavioral markers such as theory of mind accuracy ratings and response
times will be assessed as secondary outcomes in addition to physiological measures such as skin conductance.
Trait measures for alexithymia, interpersonal reactivity, and social anxiety will also be evaluated. Additionally,
we will analyze the effect of oxytocin receptor gene variants and how these potentially influence the
primary and secondary outcome measures. Functional magnetic resonance imaging assessments will
take place at two time points which will be scheduled at least two weeks apart to ensure a sufficient
wash-out time after oxytocin treatment. The study has been approved by an ethical review board and
the competent authority.
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Discussion: Revealing the mechanisms of acute oxytocin administration, especially on the socio-affective and
-cognitive domains at hand, will be a further step towards novel therapeutic interventions regarding autism.
Trial registration: German Clinical Trial Register DRKS00010053. The trial was registered on the 8th of April 2016
Keywords: Autism spectrum disorder, Oxytocin, Emotional reactivity, Social motivation, Social reward, Empathy, Theory
of mind, fMRI, Oxytocin receptor gene
Background
Autism Spectrum Disorders (ASD) are neurodevelop-
mental disorders characterized by deficits in social inter-
action and communication [1]. These include a broad
variety of symptoms, ranging from a lack of interest in
personal relationships to more subtle difficulties in man-
aging complex social interactions. Neuroimaging studies
on ASD were able to relate social impairments to spe-
cific dysfunctions in neural networks involved in pro-
cessing social information such as the dorsal anterior
cingulate (dACC), the precuneus, the anterior insula
(AI) and the temporo-parietal junction (TPJ) [2, 3].
Recent literature suggests that oxytocin (OXT) plays a
crucial role in social behavior. A single dose of intranasal
OXT has been shown to increase in-group trust and fix-
ation on the eye region, ease affect and face recognition,
and improve empathy and Theory of Mind (ToM), pair
bonding and affiliation, motivation, social cognition and
social stress regulation in healthy participants, thus, a
large range of social behaviors [4–9]. Based on emo-
tional processing experiments, it has been suggested that
amygdala reactivity mediates OXT effects on behavior
[10, 11]. The amygdala is an oxytocin receptor (OXTR)
rich area. OXT’s impact is, however, not limited to areas
that possess OXTRs, because the areas that do, such as
the amygdala, interact with other neurotransmitter sys-
tems, for example with dopamine and serotonin [5, 12].
These interactions may explain OXT findings in the pre-
frontal cortex (PFC) during altruistic interactions, as
well as activation in the temporal lobe and the insula
when emotions are processed [13]. The structure of a
brain region and its activation patterns may also be
influenced by genetic variations such as polymorphic
variants in the promotor region of the OXTR gene, and
by epigenetic mechanisms, such as methylation, which
may in turn be related to individual differences in social
behavior. Interestingly, hypermethylation of the OXTR
gene, meaning less available OXTR mRNA, has been related
to ASD and OXTR methylation influences social perception
processes [14], which are impaired in ASD patients [15].
A recent meta-analysis, which included randomized
clinical trials from January 1990 to September 2013
showed promising effects of OXT interventions on
autistic traits, especially regarding emotion recogni-
tion and eye-gaze behavior [16]. The meta-analysis
included seven independent studies with a total sam-
ple size of N = 95 male ASD patients. Significant de-
crease in repetitive behavior after OXT administration
was found [17, 18], however not consistently [19].
Four studies investigated OXT effects on communica-
tion and social emotional processing. Two of these
studies examined eye-gaze, one which reported an in-
creased fixation pattern on the eye regions of pre-
sented stimuli after OXT administration [20], the
other reporting no treatment effects on eye-gaze [19].
The remaining two studies evaluated OXT effects on
emotion processing and revealed improved affective
speech recognition after OXT administration [21] and
increased performance in the Reading-the-Mind-in-
the-Eyes task [22], which has been proposed to index
ToM capacities [23]. However, no significant treatment-
related improvement of emotion recognition was found in
the University of New South Wales (UNSW) Facial Emo-
tion Task [19]. ASD patients displayed increased sensitiv-
ity to complex social cues (i.e. unfair behavior) during a
ball-tossing game and became more discriminative in their
cooperative behavior, after receiving OXT [20]. Des-
pite specific findings on OXT’s beneficial role on
emotion recognition and quality of life measures [18],
OXT did not consistently show improvements on the
core symptoms of ASD.
Our own literature search (PubMed, Google Scholar,
until May 30th 2016) revealed that since this initial meta-
analysis on OXT effects in autism, eight further studies
have been published that investigated OXT effects on
ASD patients. Long-term OXT treatment reveals im-
provements in social reciprocity [24] and social interaction
questionnaires [25] in ASD patients, while the findings of
beneficial effects of acute OXT on social cognition are
inconsistent [26, 27]. Implicit social processing was
improved in ASD patients after acute and long-term OXT
administration [24, 28]. Furthermore, salience of social
stimuli increased significantly after long-term OXT
administration [24] and reciprocal social interaction is
associated with increased orbitofrontal cortex (OFC)
activity after acute OXT administration [29].
Caregiver-rated questionnaires showed an improve-
ment in social and developmental behavior of children
with ASD, after long-term OXT administration [30]. In
ASD patients, OXT increases trust in spite of preceding
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unfair treatment. These findings are accompanied by
reduced amygdala, hippocampus and medial temporal
gyrus activity compared to the PLC group [29]. Behav-
ioral responses of ASD patients in a complex vicarious
social pain task were not related to brain activity in the
AI (as they were in healthy controls (HCs)), but rather
to activity in the hippocampus [3]. OXT effects on
empathy-evoking pictures did not significantly differ
from those in the PLC group [31]. Cognitive and emo-
tional empathy measured with physiological tools such
as skin conductance responses (SCR) was equal in ASD
patients and HCs, whereas mood ratings were signifi-
cantly different between the groups [32]. It has previ-
ously been shown that ASD patients do not have a
deficit in empathy per se, but that the deficit observed in
individuals with an ASD diagnosis is rather related to
increased alexithymia [33, 34]. Thus, patients do per-
ceive negative affect as strong as HCs, but they are not
able to translate this perception into a behavioral report
of their affective state, when they are asked to state their
mood and arousal [32].
Given these partially inconsistent results, the most
recent review on OXT effects on ASD by Lee et al. [35]
discusses whether the promising expectations of OXT as
a potential treatment for ASD can still be maintained.
The authors conclude that there is sufficient evidence
for OXT to be a potential therapeutic for ASD and that
further research should be carried out [35]. The same
conclusion was reached by Meyer-Lindenberg and
colleagues [5] who particularly emphasize the need
for elaborate social cognition paradigms to determine
potential modulatory OXT effects on corresponding
neural networks [5].
The study at hand is part of a bigger autism research
consortium - the ASD-Net, funded by the German
Federal Ministry of Science (BMBF). The ASD-Net
examines autism from many different angles, which
allows each separate study to focus on very specific
aspects in well characterized ASD populations. The
present study is based on previous findings and satisfies
the contemporary necessity of basic research to investi-
gate the acute OXT effects on neural activity related to
diverse social processes in ASD. The paradigms which
are chosen for this study cover a wide range of socio-
affective processes, raging from emotional reactivity to
social reward, empathy and ToM.
AIM
The primary aim with this clinical trial is to identify
OXT’s acute mechanism of action on neural network
activity and relate these to improvements in social
cognitive skills in ASD patients. We will further investi-
gate the differences between ASD patients and HCs. The
results of this study may ultimately lead to the provision
of care for social deficits that accompany ASD. Further-
more, a concomitant project in which the OXTR geno-
type will be determined may enable us to specifically




This study description is in accordance with the Consol-
idated Standards of Reporting Trials (CONSORT) guide-
lines that are published for the evaluation of randomized
controlled trials [36].
Trial design
This clinical trial is a multi-centered, two-arm, random-
ized, double blind placebo-controlled study with a cross-
over design. Three visits and two functional magnetic
resonance imaging (fMRI) assessments will take place
for the participants of both groups (ASD and HC). The
first visit includes a medical interview and an explan-
ation of the informed consent; this visit determines
whether the participant can be included in the study
(T0). Once the participant is eligible to participate, he
will be randomized to arm A or arm B, which deter-
mines whether he receives OXT or placebo (PLC) at the
next visit. During the next visit (T1) the OXT or PLC
administration and the first fMRI assessment will take
place. The next visit (T2) will include the same measure-
ments as T1 and will be scheduled approximately two
weeks after T1, to ensure no carry-over effects if OXT
had been administered at T1. After completion of T1
and T2 each participant (HCs and ASD patients) will
guess which nasal spray they have received (Fig. 1).
Ethical consideration
This clinical trial has been approved by the leading
ethics committee of Lübeck University, the concomitant
ethical board of Leipzig and the higher federal authority:
Bundesinstitut für Arzneimittel und Medizinprodukte
(BfArM) in Bonn. Approval of local ethics has been
obtained in centers at which ASD patients will be re-
cruited. The study will be conducted in compliance with
the guidelines for Good Clinical Practice and the Declar-
ation of Helsinki. Prior to testing participants' informed
consent will be acquired. This trial is registered in the
German Clinical Trial Register (DRKS00010053).
Participants and procedure
Patients will be recruited from outpatient clinics across
Germany. Recruitment will take place for both sites
(Leipzig and Lübeck) simultaneously until the desired
sample size is reached. Nurse practitioners at the clinics
are asked to provide an envelope containing study infor-
mation (and an entry form) to all ASD patients who are
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eligible for study participation based on information
from their medical record. If interested in participation,
the entry form will be completed and sent to the
researchers, who will then contact the participant by
phone to provide further study information and to
address questions. Those willing to participate are asked
to fill out a screening questionnaire. After receipt of the
completed questionnaire, the researcher will contact the
patient once more to discuss the screening outcome and
to review all eligibility criteria. Afterwards the patient
will be invited to the respective research site for T0. The
informed consent form will be provided for the
participant at least 24 h before the appointment T0 to
allow for sufficient time to prepare questions already
before T0. At T0 the study doctor will inform the patient
about all risks and benefits of the study. After this
consultation the participant will have sufficient time to
decide whether he would like to participate in the study
or not. If the participant agrees, the informed consent
form will be signed and collected. A copy will be handed
out to the participant. Healthy controls will be recruited
via in-house databases until each patient has a suitable
match. After contacting and controlling for HCs eligibil-
ity for the study, the same procedure as for the patients
will be followed.
Eligibility
ASD patients will be eligible participants if: 1) they are
male, 2) they are aged between 19 and 40 years, 3) their
mother tongue is German, 4) they have an IQ above 70,
5) they have one of the following diagnoses: Infantile
Autism, (F84.0 according to ICD-10), Asperger Syn-
drome (F84.5 according to ICD-10), or Atypical Autism
(F84.1 according to ICD-10), 6) they have given written
informed consent. ASD patients are not eligible to
participate if: 1) they have a BMI lower or equal to 18 or
above or equal to 30, 2) they show MRI-contraindications
such as having a pacemaker or being claustrophobic, 3)
they have oxytocin contraindications such as arrhythmia,
4) they are suicidal, or 5) they have a history of metabolic,
endocrinologic or cardiovascular diseases.
Healthy controls are matched to ASD patients regard-
ing age, gender and IQ; additional inclusion criteria are:
1) no autistic traits (Autism Quotient (AQ) below 32.
This questionnaire is validated as a screening instrument
and allows the detection of autistic traits. The cut off
score of 32 and higher complies with previous autism re-
search [37]. 2) No first or second degree relatives with
autism (participants will be asked for the occurrence of
Autism within their family). Further exclusion criteria
for HCs include: 3) a history of psychological or neuro-
logical illnesses and 4) current psychological or psychi-
atric treatment (participants will be asked to provide this
information, before further consideration).
Sample size
The sample size is calculated for the two primary
outcomes: 1) the effects of the OXT treatment on the
neural system functioning in the ASD population and 2)
the comparison between the ASD and the HC group in
the placebo condition. The first comparison for the
power calculation is the cross-over comparison of the
OXT effects on neural network activity in the ASD pa-
tient group, because the recruitment plan is determined
by the ASD patient group. Meta-analytic estimates of
intranasal OXT effects on the behavior of ASD patients
indicated a medium effect size of approximately d = 0.60.
We expect neural OXT effects to be bigger than
behavioral OXT effects, because OXT has a stronger
penetrance on the brain. Therefore, we adjusted the
Fig. 1 Study Design
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effect size for OXT’s influence on brain activity to d =
0.65. For all power calculations, a power of 80 % and a
significance level of alpha = 0.001 was chosen and the
analyses were carried out with PASS12. To obtain suffi-
cient power for two-tailed t-test analyses in a cross-over
design, N = 88 ASD patients need to be included in the
analyses. Based on our prior experiences with ASD
patients in behavioral and fMRI studies [3, 38] and the
relatively short duration of the current study led to a
drop-out estimation of 13 %. To allow for this drop-out,
we need to initially recruit N = 102 patients. Due to the
one on one matching it is necessary to include as many
HCs as patients (N = 88). Recruitment for HCs will thus
continue until each ASD patient has a proper match.
Randomization
After completion of baseline assessment, ASD patients
will be assigned to either arm A (T1: OXT, T2: PLC) or
arm B (T1: PLC, T2: OXT). The order will be deter-
mined with a block randomization of 2 or 4 participants
per block for arm A and arm B. The order of the three
different experimental paradigms is also randomized
with a fixed block size of six (123/132/213/231/312/321)
so that each combination of assessment order is possible
to ensure equivalent OXT levels for all paradigms. Thus,
a second randomization list for the different paradigms,
one for arm A and one for arm B, will ensure that each
order of the experimental paradigms will be equally
distributed in both arms.
The randomization lists will be independently gener-
ated for both sites (Leipzig/ Lübeck) to guarantee
balancing for both sites. Thus, there will be three lists
for each site, one arm-randomization list and two para-
digm randomization lists. The lists are solely generated
for the ASD population; HCs will be matched to the pa-
tients. The matching is also done by each center separ-
ately. Every matched participant will receive the same
experimental order as the corresponding ASD patient.
Processes and interventions
Before participants will be included in this study, they
will come to one of the research sites (Leipzig or
Lübeck) and will be carefully informed about the aim,
contents, the duration and potential risks and benefits of
this study. They will be informed that their participation
is voluntary and that they can decide to no longer
participate at any moment.
During the doctoral interview each participant will be
examined to ensure that all inclusion and no exclusion
criteria apply. The participant will especially be informed
about not drinking excessive amounts of water before
nasal spray administration, due to the potential anti-
diuretic side effects of OXT that may lead to a water-
intoxication.
If the participant decides to take part in the study and
has no more open questions, after having had sufficient
time to consider it, he can sign the informed consent
and will be included in the study. Afterwards the partici-
pant will be asked to fill in questionnaires, which will
take 1 – 2 h of time.
If inclusion/ exclusion criteria have not changed at the
time of the second visit, the experimental procedure will
be started. If participants are willing to participate in the
concomitant genetic project, which determines their
OXTR genotype, they will be asked to give a saliva sam-
ple. Pulse and blood pressure will be measured before
and after nasal spray administration, to monitor OXT’s
potential side effects and inclusion/ exclusion criteria.
Physiological data, such as fixation patterns, pupil dila-
tion, heart rate, respiration, and skin conductance pat-
terns will also be acquired during the fMRI assessments.
Approximately 45 min before the fMRI-measurement
starts, each participant receives a single dose (24 IU) of
the nasal spray which he will self-administer. The par-
ticipant is carefully instructed on how to administer the
nasal spray. Each puff contains 2 IU (only Oxytocin
nasal spray), thus in total 6 puffs need to be adminis-
tered in each nostril to reach 24 IU.
Before the fMRI-measurements start, the eye-tracker
will be calibrated and a habituation measurement of 5-7
min will take place. During this time, the participants
will not have a specific task.
The procedure followed at T1 will be repeated at T2.
After T2 the participant will be paid for his timely




The emotional matching task was selected as a well-
established fMRI task investigating emotion processing.
In order to further optimize the task, we adapted the
original emotional matching paradigm [39] by choosing
more comparable control stimuli. Participants are pre-
sented with a total of 60 faces (20 positive, 20 neutral,
20 negative), 60 social scenes (20 positive, 20 neutral, 20
negative) and 60 non-social scenes (20 positive, 20
neutral, 20 negative). This stimulus set results in 9
conditions: positive faces, neutral faces, negative faces,
positive social scenes, neutral social scenes, negative so-
cial scenes, positive non-social scenes, neutral non-social
scenes and negative non-social scenes. Each presented
picture consists of three single pictures arranged in a
pyramidal disposal, in which the picture on the top is
identical to one of the pictures below. Participants need
to decide by button press whether the left or the right
picture matches the one on top. Each stimulus picture
will be presented for 4 s and 4 pictures of the same
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category (e.g. positive social scenes) constitute one block.
The different category blocks will be presented in a
randomized manner. This experiment consists of two
parallel stimulus sets so that version A can be shown at
one visit and version B can be shown at the other visit.
Social orienting, social reward anticipation, and
consumption
As social rewards play a crucial part in almost all aspects
of life we chose the social incentive delay (SID) para-
digm [40–42] as a well-established tool to investigate its
neural underpinnings. The paradigm is an adaption of
the monetary incentive delay (MID) [43] (which will be
also examined as a control condition) and has been
shown to successfully elicit ventral striatal activity, also
in patients with ASD [44]. In the MID/SID, a potential
gain depends on the participant’s ability to hit a button
in time whenever a target symbol appears on the screen.
Distinct cues preceding the target inform the participant
whether a reward can be won. Each trial will involve two
phases: the anticipation phase and the consumption
phase. During the anticipation phase, the cue will be
presented for 250 ms signaling the type of potential re-
ward, that is, wallets with money in the MID and smil-
ing faces for SID or empty wallets and neutral faces
respectively for no reward. Circles and squares indicate
the reward type. After a delay period a target symbol will
appear on the screen and a button has to be pushed
within a set time window (adapted for individual reaction
time assessed prior to the experiment). In the consump-
tion phase, success will be acknowledged by presenting
the picture of the reward. After each trial, participants will
be shown a blank screen as a low-level baseline. The para-
digm consists of two parallel stimulus sets for the SID and
the MID which will either be shown at T1 or T2.
Empathy, compassion and theory of mind
The EmpaToM is a novel fMRI paradigm that investi-
gates empathy and theory of mind (ToM), within one
task [45, 46]. Participants will be presented with 40 short
(~15 s) video clips of 10 actors, each recounting four
putatively autobiographic episodes. These narrations are
either neutral or emotionally negative and demand
either theory of mind or factual reasoning. In total there
are four conditions: neutral + non-ToM, neutral + ToM,
emotional + non-ToM, neutral + non-ToM. Each video is
followed by the question “How do you feel?” and partici-
pants are supposed to give an answer on a visual
analogue scale ranging from negative – positive. After-
wards participants are asked “How much compassion do
you feel?” and are again supposed to answer on a visual
analogue scale ranging from none – very much. Before
the experiment begins, participants are carefully
instructed and an explanation of what is meant by the
term compassion is given. Finally, participants will have
to answer a multiple choice question that relates to the
content of the video, and is either asking for information
that requires ToM capacities or for information that re-
quires factual reasoning. The video trials are presented
in a randomized manner. This experiment consists of
two stimulus sets so that version A can be shown at one
visit and version B can be shown at the other visit.
Resting state brain activity
Resting state (rs)-fMRI identifies baseline brain activity of
spontaneous blood-oxygen-level dependent (BOLD) fMRI
signals and its analysis reveals changes in organization of
large-scale functional networks, including oxytocinergic
and related networks. Participants will be instructed to lie
in the scanner with their eyes open and to try focusing on
the presented fixation cross.
Structural brain markers
The structural measurements in this clinical trial will
serve the comparison between ASD patients and
HCs, not the comparison of the treatment groups
(OXT vs. PLC).
Diffusion tensor imaging (DTI) One DTI measure-
ment will be acquired from each participant. Participants
will be asked to lie particularly still during this
measurement.
T1-weighted image A three dimensional T1-weighted
MR image will be obtained from all participants. All im-
ages will be examined and approved for inclusion by the
study doctor at the respective institute.
Primary outcome
Neural correlates of socio-affective and -cognitive tasks
in ASD patients and HCs will be assessed after PLC and
after OXT administration at two time points (cross-over
design) using fMRI. For this study the primary outcome
measure will be the neural network activity that is asso-
ciated with the different social paradigms.
Secondary outcomes measures and potential outcome
mediators
Secondary outcomes entail behavioral measures that are
collected during the fMRI sessions, including response
times and ratings. Further, physiological measures that
indicate affective arousal related to dACC and AI activity
such as pupil dilation [see [47] for further details] heart
rate and skin conductance responses are collected in the
fMRI and fixation patterns and respiratory frequency
will be recorded.
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In addition to the secondary outcome variables,
multidimensional aspects of autism and participants
personality traits will be assessed with a questionnaire
test battery, including: basic sociodemographic question-
naire, basic diagnosis and medication questionnaire
(for patients only), number-symbol-test, digit-repetition
test (part of the Hamburg-Wechsler-Intelligenztest für
Erwachsene (HAWIE, since 2012 WAIS-IV)), brief
symptom inventory (BSI-53) [48], WHO Disability
Assessment Schedule [49], childhood trauma screener
[50], clinical global impression scale (for patients only)
[51], Trail Making Test A and B [52], vocabulary know-
ledge test (WST) [53], behavioral inhibitory scale (BIS)
and behavioral approach scale (BAS) [54], Barratt
impulsiveness scale [55], positive and negative affect
schedule, interpersonal reactivity index (IRI) [56], To-
ronto alexithymia scale (TAS-20) [57], social interaction
anxiety scale (SIAS) [58], Beck depression inventory
(BDI-2) [59, 60], autism quotient (AQ) [37] state-trait-
anxiety index – state (STAI-S) and state-trait-anxiety
index – trait (STAI-T) [61], and an intelligence quotient
(IQ) – test will be done. All data information will be




Raw data of all key variables will be tested for nor-
mality prior to analysis. Appropriate transformations
(or non-parametric tests) will be conducted accord-
ingly. Analyses will be done using repeated-measures
analysis of variance (AN(C)OVA) and mixed models
as primary designs. Difference scores will be calcu-
lated on every dependent variable for participant
(ASD vs. HC) and treatment (OXT vs. PLC) groups.
All measures will be compared between participant
(ASD vs. HC) and treatment (OXT vs. PLC) groups
and interaction effects (group x treatment) will be ex-
plored. Trait questionnaires may additionally be used
as regressors when they can potentially explain behav-
ioral differences between participant or treatment
groups. After the T1 and the T2 visit, participants will
be asked to guess whether they have received OXT or
PLC. This information allows us to calculate a chi
square test after unblinding, to check whether partici-
pants knew or did not know which nasal spray they
received.
Task-related functional MRI analysis
All fMRI data will be preprocessed with SPM and after-
wards statistical analysis will be carried out using the
general linear model [62]. For all experiments, onset and
duration of the block or event will be modeled. The
respective regressors will be convolved with a canonical
hemodynamic response function (HRF) and head motion
will be accounted for by modeling the six motion param-
eters for each subject. If the head movement exceeds the
usual tolerance of 3 mm, additional movement correc-
tions will be carried out. Differences between participant
(ASD vs. HC) and treatment (OXT vs. PLC) groups and
interactions between participant and treatment groups
on BOLD signal changes will be evaluated for each task
(ANOVA and/ or t-tests). Whole brain and paradigm-
specific region of interest (ROI) analysis, based on infor-
mation from previous studies assessing these paradigms
and meta-analyses of the investigated functions will be
done. For the emotional matching task, two main effects
(sociality and emotional valence) as well as the inter-
action effect (sociality x emotional valence) will be calcu-
lated. In the social and monetary incentive delay task
two main effects (task and phase) will be calculated as
well as the interaction effect (task x phase). The Empa-
ToM will include main effect contrasts of empathy and
ToM. For this paradigm we may for example use the AI
and the dACC as ROIs, because these regions have con-
sistently been identified with empathy [45, 46]. Further-
more valence and compassion responses might be added
as parametric modulators to further explain task-related
brain activation. All task-related main effects and inter-
actions will be calculated for participant (ASD vs. HC)
and treatment (OXT vs. PLC) groups. Personality trait
scores may also be added as regressors in the fMRI ana-
lysis to investigate secondary research questions and ex-
plain specific variance. All interaction effects will be
followed up and more detailed investigations will be car-
ried out. Additionally, we will extract the peak BOLD-
fMRI activation levels from ROIs that have previously
been reported in these paradigms or meta-analyses, and
import the extracted values into SPSS or R for additional
statistical calculations. Furthermore, we plan to perform
connectivity analyses with paradigm-specific peak re-
gions. The results of each fMRI paradigm will be ana-
lyzed and published separately, before the results of
multiple paradigms will be combined to generate an
overarching picture of OXT’s effects on social cognition/
social functioning.
Resting-state functional MRI analysis
The rs-fMRI data will be preprocessed with SPM and
afterwards statistical analysis will be performed. Nuis-
ance covariates will be removed from the data including
six head motion parameters. For functional connectivity
calculation, seed regions will be defined based on the ac-
tivation peaks observed in the task-related fMRI con-
trasts of the present study and in previous studies on
related functions. We will perform voxel-wise correl-
ation analyses to generate functional connectivity maps.
Preckel et al. BMC Psychiatry  (2016) 16:329 Page 7 of 10
T-tests will be used to extract those brain regions that
show significant positive correlations with our peaks.
The rs-fMRI measures will, after primary analysis, be
contributed to a consortium, and multiple researchers
may make use of the data and choose their analysis tool
of preference.
Diffusion tensor imaging analysis
Analysis of DTI data will be performed using state-of
the art techniques. The DTI data acquired in this
study does not belong to our primary or secondary
outcome measures. Exploratory analysis may be con-
ducted after investigating the primary and secondary
outcome measures. The main interest with these DTI
data is to identify group differences between ASD pa-
tients and HCs. The DTI data will be contributed to
a consortium, and multiple researchers may make use
of the data and choose their analysis tool of
preference.
T-1 weighted image analysis
A structural MPRAGE t1-weighted image will be ana-
lyzed and preprocessed with SPM. It will mainly be used
as a reference image for the functional paradigms.
Furthermore, the potential differences between groups
will be analyzed.
All secondary outcome measures will be analyzed
analogously.
Discussion
The neural processes and the specificity of OXT effects
on the socio-affective and –cognitive functioning are not
fully understood. Intranasal OXT shows promising
effects on the core symptoms of social cognition and
affected brain systems in ASD. To date, there is no
pharmacological treatment for the social deficits in ASD.
Currently, three medication classes that aim at treating
repetitive behavior (neuroleptics, [63–65], and SSRIs
[66]), hyperactivity, impulsivity, disinhibition and in-
attention (psychostimulants [67]) are highly studied in
ASD research. However, none of these pharmacological
treatments challenges the social deficits of ASD. The
social deficits are the focus of this clinical trial and we
will evaluate whether OXT can improve these deficits in
ASD patients by systematically investigating different
levels of social behavior using various methods. Due to
this multi-measure approach and the use of different
paradigms, this study provides new insights in the
functional mechanisms of OXT on the core symptoms
of ASD patients.
The broad spectrum of ASD poses an additional
challenge to develop adequate treatments for autism per
se. We will concentrate on three diagnoses of ASD in
this clinical trial: Infantile Autistic Disorder, Asperger
Syndrome and Atypical Autism and only focus on male
adults aged between 19 and 40 years. The within-
subjects comparisons in the ASD group (OXT vs. PLC)
and the comparisons to the healthy control group in
both treatment states will enable us to identify
treatment-related changes.
One aim of this clinical trial is to successfully pre-
dict, by using neurobiological, behavioral, environ-
mental, and genetic information, whether intranasal
OXT is a promising treatment option for patients
with Infantile Autistic Disorder, Asperger Syndrome
or Atypical Autism. A limitation that this clinical trial
shares with many studies [7, 9, 68, 69] is that only
male subjects will be tested and thus findings cannot
be generalized to women. However, this limitation
also increases the internal validity of this trial. Fur-
thermore, as acute OXT effects will be investigated,
no statements about longitudinal treatment effects
can be drawn from this trial. The simple comparison of
treatment responders with treatment non-responders
would indicate regions involved in treatment-specific
response, the possibility that patients would have
responded to alternative treatment strategies remains.
Acknowledging these limitations, we hope the study
results will assist to inform future therapeutic intervention
regarding groups with social deficits, especially ASD
patients. Findings by Yatawara [30] described above
support the assumption that OXT can have beneficial
consequences regarding social capacities and general
developmental behaviors in autistic children. These early
beneficial results in autistic children might smooth the
way for improved social skills in adulthood. The collabor-
ation within this ASD-Net will allow to directly exchange
findings and build upon each other’s results. As such, it
offers high internal validity of each trial by using reprodu-
cible experimental set-ups and by integrating knowledge
from related investigations.
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